NetTargets successfully completed the development of an AI platform to identify combination drug candidates that induce cellular reprogramming, along with insights into their mechanisms of action (MoA) for anti-aging applications.
NetTargets Inc.
30 Nov 2024
NetTargets successfully completed the development of an AI platform to identify combination drug candidates that induce cellular reprogramming, along with insights into their mechanisms of action (MoA) for anti-aging applications.
NetTargets will contribute its proprietary AI-based systems biology modeling technology to WOOJUNGBIO’s Open Innovation Project. By enabling quantitative simulation of biological responses and prediction of drug mechanisms, we are helping to shape a next-generation bioevaluation platform in the era of AI transformation.
NetTargets has been selected as one of the top 10 semifinalists among hundreds of drug discovery startups worldwide. The AI Discovery Award is an annual recognition by Nebius AI, a European AI-centric public cloud provider with global reach.
